Archive for September, 2011

Lansoprazole outruns Ranitidine in the long term battle of GERD treatment

Tuesday, September 20th, 2011

gastroesophageal reflux diseaseIn developed nations, between 20-40 percent of adults experience heartburn on a regular basis. Heartburn is characterized by a burning sensation that rises from the stomach towards the chest and neck. It has often been mistaken as angina, a symptom of heart attack. Heartburn is the primary symptom of gastroesophageal reflux disease (GERD). When left untreated for a long time, it results in the inflammation and swelling up of the esophagus, a condition called erosive esophagitis. It is estimated that over half of GERD sufferers may have erosive esophagitis.

A multicenter study conducted by the CURE Digestive Diseases Research Center and the VA Greater Los Angeles Healthcare System, found that lansoprazole provides better quality of life for long time sufferers of GERD and its associated complication, erosive esophagitis.  The study used subjects with erosive esophagitis in order to evaluate its recurrence in those who were put in long term therapy with ranitidine and lansoprazole. The subjects were put into group 1 and group 2 with each group receiving a 12 month therapy with lansoprazole and ranitidine respectively.

The results of the study showed a significant difference between the two treatment groups, specifically favoring the lansoprazole treated subjects when reduced frequency, severity and inconvenience were tested. The decreased incidence of symptom outbreaks, severity and physical difficulties are indicators that point to improved quality of life. This is why the researchers concluded that putting patients with healed erosive esophagitis on maintenance therapy with lansoprazole for 12 months led to a more improved quality of life than those put on ranitidine therapy.

Relatively new drugs (such as the proton pump inhibitor Lansoprazole CAS# 103577-45-3) have a greater treatment role in certain disorders and diseases than what they were initially approved for. In light of these developments, LGM Pharma has not only kept its focus on the market for new studies, but it has also been a consistent supplier of Lansoprazole CAS# 103577-45-3 and Ranitidine Hydrochloride CAS# 71130-06-8. By lending their hand as a responsive supplier, the company believes that it has helped to invigorate similar research efforts by pharmaceutical organizations worldwide.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

Methimazole provides a good alternative to surgery and radiation in Graves disease therapy

Tuesday, September 20th, 2011

graves-diseaseThe most common form of hyperthyroidism in the US is Graves Disease. In the recent months, it has seen a promising alternative to surgery and radioactive iodine therapy in the form of the drug, methimazole. Methimazole is an anti-thyroid drug that is usually given to patients prior to undergoing surgical thyroid removal in order to lower thyroid hormone levels in the body.

In the current medical practice, surgical removal of the thyroid gland and radioactive iodine therapy are considered the best options in the long run. However, in some European practices, staying on oral methimazole indefinitely is considered a better treatment option. This is especially true for patients who are not good candidates for surgery and radioactive therapy. Given that patients who undergo surgery and radioactive therapy usually become hypothyroid (decreased thyroid hormone levels), they need to take a supplementary thyroid hormone daily for the rest of their lives.

Now patients are faced with two options: take an antithyroid medication such as methimazole for the rest of their lives or undergo surgery and radiation treatments and then take thyroid supplements indefinitely. Either way they have to take pills everyday which resolves the issue of better convenience and therapy adherence. These two options are tied in this score. Now what about side effects? Methimazole CAS# 60-56-0 has a better side effect profile than the other two. Although it is known to cause rashes and headaches, surgery and radiation do not even stand close scrutiny since the former has inherent risks and the latter strongly increases the risk of the eye disorder, Grave’s opthalmopathy.

A study published in the European Journal of Endocrinology that compared the long term effects of 10 year therapy with methimazole with radioactive iodine therapy found that both treatments produced similar thyroid levels, cost of treatments and blood analysis results. What’s more, the patients treated with radioactive iodine had higher levels of LDL when lipid profiles were obtained as well as decreased bone densities. Except for the rare blood dyscrasias it causes, methimazole is a good alternative to the two options. Doctors and health professionals believe that it will only be a matter of time before this becomes the treatment of choice.

These results bring us down to Methimazole CAS# 60-56-0, a research molecule supplied by LGM Pharma. Apparently, the judge is still out on this drug’s role in the long term treatment of Grave’s disease. However, initial studies such as the one mentioned above as well as the steady supply chain provided by LGM Pharma to the extended research and development of this drug pave the way for its increasing importance in the treatment of Grave’s disease.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

Epirubicin improves HER2-positive breast cancer survival

Tuesday, September 13th, 2011
her2-receptor

The HER2 receptor dimer transmembrane signal transduction pathway

In the recent decades, women’s health has taken center stage. No longer hidden in obscurity, breast cancer emerged as a growing concern for women all over the world. The disease does not just strike women, it affects children and men as well, albeit indirectly. The role of the woman as a mom and earning partner in a family unit can be severely undermined by the disease. The growing cost of cancer treatment, poor prognosis and long term uncertainties brought on by breast cancer can shake even the most stable of families. For women with HER2-positive breast cancer, the battle is even harder.  This is because it is more aggressive than the HER2-negative type. In about 1 of every 5 breast cancers, the cancer cells make an excess of human epidermal growth factor receptor 2 (HER2) through a gene mutation. What’s more, this is also less responsive to cancer treatment.

Despite all these harrowing news, there’s a light at the end of the tunnel. There are available treatments that specifically target HER2 and have so far been found to be effective. But this effectiveness comes with a price: high costs and debilitating side effects, particularly, an increased susceptibility to opportunistic infections. That is why LGM Pharma works diligently with pharmaceutical firms who have dedicated their resources and manpower to developing novel ways to combat this particular form of cancer.

Women who produce excessive HER2 can particularly benefit from an anthracycline-based chemotherapy. Anthracyclines are anticancer drugs derived from a certain strain of bacteria and is considered effective against a wider range of cancer than any other anticancer agents in the market today. A combination of data from eight randomized clinical trials published by the Journal of Cancer Institute in January 2008 supports the use of Epirubicin CAS# 56420-45-2 in women with HER2-positive breast cancer for cancer extension of cancer survival compared with non-anthracycline-based chemotherapy. Although the results show promising clinical outcomes, the medical community agrees that toxicity data and dosages need to be further investigated in order to provide patients with better clinical treatment results.

LGM Pharma recognizes the importance of women’s health in the society and as such, have extended their cooperation with research firms who are involved in addressing the health issues that plague women today. By providing a steady stream of Epirubicin CAS# 56420-45-2 to these firms, the company has allowed their research endeavors to prosper without worrying about the integrity of their results because this product pass quality regulatory tests.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

Monotherapy with Darunavir is Where the “MONET” is

Friday, September 2nd, 2011

AIDS is a global pandemic whose cure has eluded scientists and doctors for more than 2 decades. Acquired immunodeficiency syndrome (AIDS) is caused by the Human Immunodeficiency Virus (HIV) which progressively undermines the strength of the immune system until such a time that the body becomes incapable of fighting off infections and vulnerable to opportunistic infections and tumors.

As of 2009, the World Health Organization estimates that there are 33.4 million people living with AIDS, with 2.7 million new HIV infections and another 2 million deaths reported each year. Since the first infection was reported in June 1981, drug companies worldwide have been coming up with new therapies and drugs to combat the rapidly growing pandemic. However, a complete viral cure remains elusive even now, with the best standard treatment at the moment being called triple drug arm antiretroviral therapy (ART). Highly active antiretroviral therapy (HAART) has proven to be very successful since its introduction in 1996. A typical HAART therapy consists of a protease inhibitor and two nucleoside analogue reverse transcriptase inhibitors (NARTIs). NARTIs such as Zidovudine CAS# 30516-87-1, Didanosine CAS# 69655-05-6 and Emtricitabine CAS# 143491-57-0 slow down the disease progression by interfering with the DNA synthesis. Protease inhibitors, on the other hand, such as Ritonavir CAS# 155213-67-5 prevent the replication of the HIV virus by inhibition of the protease enzymes.

About the MONET study

According to the MONET study published last year by the manufacturer of Darunavir, Tibotec, a Darunavir-boosted monotherapy (Darunavir-ritonavir 800-100 mg once daily) produced similar outcomes to the standard triple drug regimen after 48 weeks in therapy. The viral loads from both groups were statistically equivalent (viral load suppression less than 50 copies/mL) suggesting that the boosted monotherapy is as clinically effective as the triple drug regimen.  This finding is a promising beacon of light in the narrow tunnel currently traversed by AIDS therapy. Given enough research data, Darunavir Ethanolate CAS# 635728-49-3 monotherapy will simplify the current HAART in AIDS/HIV treatment, potentially resulting in an increase in patient adherence to therapy, reduced treatment costs and side effects.

LGM Pharma & AIDS Treatment Research

LGM Pharma currently supplies protease inhibitors and NARTIs to universities and pharmaceutical labs worldwide for research and development purposes. Just like its steadfast backing of cancer research, the company is actively engaged in AIDS treatment research. Just like the pharmaceutical companies that LGM Pharma currently supplies pharmaceutical products to, it understands the importance of putting quality above all else. It supplies only cGMP certified products to its suppliers while continuously monitoring every detail of its manufacture and movement down the supply chain which in turn gives its clients the confidence to go about their research and development of therapies for the AIDS pandemic.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.